Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood.
Cell-surface antigen expression of hematopoietic stem cells has a crucial role in characterizing cell subpopulation with distinct functional properties. The Eph receptors are the largest receptor tyrosine kinase family being involved in processes like vascular remodelling during development and physiological and pathological angiogenesis. Some Eph/Ephrin members are expressed in hematopoietic cells. The ability to isolate purified cell populations co-expressing CD34 and CD133 antigens as most commonly used markers for identification of hematopoietic progenitors has provided the opportunity to identify their surface-receptor profile. As positively expressed CD34 and CD133 cells take place not only in hematopoietic but also in endothelial differentiation, we aimed to define the Eph/Ephrin characteristic of these cells and relate these findings to new therapy strategies. Positive selections of CD34 and CD133 cells from PBPC in lymphoma patients were performed using magnetic beads and AutoMACS (Miltenyi Biotec) device. The purity of isolated cells was tested by flow cytometry. Immunocytochemistry was used to assess the Eph/Ephrin expression profile of positively selected samples. Our study revealed that all samples (10 from CD34+ and 8 from CD133+ cells) expressed one or more of Eph/Ephrin antigens in different proportions. All CD34+ cell samples, and 6 of 8 in the CD133+ cell fraction were strongly immunoreactive for EphA2. EphB2 was strongly expressed in all CD133+ cases, but 50% of the CD34 positive group lacked or weakly expressed this receptor. EphB4 was negative in 9 of 10 CD34+ cases and in all CD133+ cells. Thus, we have shown the surface marker profile of positively selected CD34 and CD133 cells in leukapheresis samples from lymphoma patients with regard to Eph/Ephrin receptors and discussed their biological clinical potential.
Lab for Cellular Therapy, The National Hospital-The Norwegian Radium Hospital, University of Oslo, Oslo 310, Norway.
P
P
Lazarova
Q
Q
Wu
G
G
Kvalheim
Z
Z
Suo
K W
KW
Haakenstad
K
K
Metodiev
J M
JM
Nesland
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000096:biosynthesis*; D018952:Antigens, CD34 / Q000096:biosynthesis*; D036342:Ephrins / Q000096:biosynthesis; D005434:Flow Cytometry; D006023:Glycoproteins / Q000096:biosynthesis*; D006412:Hematopoietic Stem Cells / Q000378:metabolism* / Q000648:ultrastructure; D006801:Humans; D007150:Immunohistochemistry; D007937:Leukapheresis; D008854:Microscopy, Electron; D010455:Peptides; D011956:Receptors, Cell Surface / Q000378:metabolism; D036081:Receptors, Eph Family / Q000096:biosynthesis*; D017978:Receptors, Growth Factor / Q000096:biosynthesis*
D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D036342:Ephrins; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D011956:Receptors, Cell Surface; D017978:Receptors, Growth Factor; D036081:Receptors, Eph Family